Dianthus Therapeutics Inc (NASDAQ: DNTH) on Friday, plunged -5.39% from the previous trading day, before settling in for the closing price of $36.93. Within the past 52 weeks, DNTH’s price has moved between $13.36 and $40.16.
Healthcare Sector giant saw their annual sales surged by 40.14% over the last five years. The company achieved an average annual earnings per share of -34.27%. With a float of $29.04 million, this company’s outstanding shares have now reached $32.18 million.
Dianthus Therapeutics Inc (DNTH) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Dianthus Therapeutics Inc is 27.05%, while institutional ownership is 86.24%. The most recent insider transaction that took place on Sep 09 ’25, was worth 700,000. In this transaction CFO & CBO of this company sold 20,000 shares at a rate of $35.00, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 09 ’25, when Company’s Officer proposed sale 20,000 for $31.80, making the entire transaction worth $636,000.
Dianthus Therapeutics Inc (DNTH) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.74 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.6) by -0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -34.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.40% during the next five years compared to 40.14% growth over the previous five years of trading.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Trading Performance Indicators
Dianthus Therapeutics Inc (DNTH) is currently performing well based on its current performance indicators. A quick ratio of 13.12 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 286.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.25, a number that is poised to hit -0.89 in the next quarter and is forecasted to reach -3.55 in one year’s time.
Technical Analysis of Dianthus Therapeutics Inc (DNTH)
Analysing the last 5-days average volume posted by the [Dianthus Therapeutics Inc, DNTH], we can find that recorded value of 0.78 million was better than the volume posted last year of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 36.86%.
During the past 100 days, Dianthus Therapeutics Inc’s (DNTH) raw stochastic average was set at 77.81%, which indicates a significant increase from 6.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.17 in the past 14 days, which was higher than the 1.62 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.16, while its 200-day Moving Average is $22.43. Now, the first resistance to watch is $36.84. This is followed by the second major resistance level at $38.73. The third major resistance level sits at $39.86. If the price goes on to break the first support level at $33.82, it is likely to go to the next support level at $32.69. Should the price break the second support level, the third support level stands at $30.80.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Key Stats
Market capitalization of the company is 1.39 billion based on 32,188K outstanding shares. Right now, sales total 6,240 K and income totals -84,970 K. The company made 190 K in profit during its latest quarter, and -31,630 K in sales during its previous quarter.
